An Open-label Study of Trastuzumab Emtansine (T-DM1) vs Capecitabine + Lapatinib in Patients With HER2-positive Locally Advanced or Metastatic Breast Cancer (EMILIA)
This study is ongoing, but not recruiting participants.
Study NCT00829166
Information provided by Genentech
First Received on January 22, 2009.
Last Updated on April 22, 2013
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
